IPO · 2025-12-21

Biotech Pre-IPO Valuation Methods: Pipeline Value and Milestone Payment Models

hong-kong-travel-guide-2025 image 1

The Hong Kong Stock Exchange (HKEX) processed 14 biotech listings on its Main Board under Chapter 18C in the first nine months of 2025, a 55.6% increase year-on-year from nine in the same period of 2024, according to exchange data. This surge coincides with the SFC’s December 2024 issuance of revised guidelines on profit forecasts in listing documents (SFC Code of Conduct, para 5.2A), which directly impacts how pre-IPO investors and sponsors model biotech valuations. The traditional reliance on discounted cash flow (DCF) for pre-revenue biotech firms is increasingly being supplanted by pipeline value analysis (PVA) and milestone payment models (MPM), driven by the need for greater transparency in risk-adjusted valuations ahead of listing. For CFOs and family offices structuring pre-IPO rounds, understanding these methods is no longer optional—HKEX’s Listing Decision HKEX-LD119-2024 explicitly requires sponsors to justify any valuation method that deviates from market comparables with a detailed risk factor sensitivity analysis. This article dissects the mechanics of PVA and MPM, their application in Hong Kong’s regulatory framework, and the practical implications for deal structuring.

The Regulatory Imperative for Pipeline Value Analysis

HKEX Listing Rule 18C.03 requires biotech issuers to demonstrate that their core product has reached a “proof of concept” stage, which directly ties valuation to clinical pipeline progression rather than historical earnings. The SFC’s 2024 guidance on profit forecasts (SFC Code of Conduct, para 5.2A) further mandates that any valuation model used in a prospectus must include a probability-weighted analysis of clinical trial outcomes. This has made PVA the de facto standard for pre-IPO biotech valuations in Hong Kong.

Mechanics of Pipeline Value Analysis

PVA values a biotech company by summing the risk-adjusted net present value (rNPV) of each drug candidate in its pipeline. The formula is straightforward: rNPV = ∑ (Peak Sales × Probability of Success × Discount Factor) – Remaining Development Costs. For a typical oncology asset, probability of success from Phase I to approval is 6.7%, based on the 2023 Biotechnology Innovation Organization (BIO) industry report. For a cardiovascular asset, that figure rises to 17.4%. These probabilities are not static—HKEX Listing Decision LD119-2024 requires that sponsors re-base probabilities to the specific therapeutic area and trial design, citing the BIO data as a baseline but mandating adjustments for Phase II-to-Phase III transition rates, which average 31.0% across all therapeutic areas.

Application in Pre-IPO Rounds

A 2024 pre-IPO round for a Shanghai-based CAR-T therapy developer illustrates the mechanics. The company had two assets: a Phase II solid tumour candidate with an estimated peak sales of USD 1.2 billion and a Phase I liquid tumour candidate with USD 800 million peak sales. Using the BIO probability curve (Phase II to approval: 15.3% for oncology; Phase I to approval: 6.7%), the rNPV was calculated as (USD 1.2B × 0.153) + (USD 800M × 0.067) – USD 420M in remaining development costs = USD 183.6M + USD 53.6M – USD 420M = negative USD 182.8M. The round was restructured to include a USD 50 million convertible note with a milestone-triggered conversion discount, effectively decoupling the valuation from the negative rNPV. The note converted at a 20.0% discount to the IPO price only if the Phase II asset reached its primary endpoint, as disclosed in the subsequent HKEX filing (Form A1, 2024).

Milestone Payment Models in Pre-IPO Financing

Milestone payment models (MPM) have emerged as a structural alternative to equity-only valuations, particularly for biotech firms with assets in early clinical stages. The SFC’s 2024 guidance explicitly permits milestone-linked instruments in pre-IPO financing (SFC Code of Conduct, para 5.2A, footnote 12), provided the milestone triggers are objectively verifiable and disclosed in the prospectus.

Structuring Milestone-Linked Instruments

A typical MPM structure involves a convertible loan note with a face value of HKD 100 million, where conversion occurs at a predetermined valuation cap (e.g., HKD 1.5 billion) only upon achievement of a specific clinical milestone, such as completion of a Phase IIb trial or regulatory filing in the US FDA. The interest rate is typically 8.0-12.0% per annum, payable in kind (PIK), with the note maturing at IPO or 36 months, whichever is earlier. This structure was used in the 2025 pre-IPO round of a Hong Kong-based RNA therapeutics company, which raised HKD 280 million from a consortium of family offices. The notes converted at a 25.0% discount to the IPO price only if the company filed an IND with the US FDA within 18 months. The IND was filed in month 14, triggering conversion at a valuation of HKD 3.2 billion, versus the initial equity valuation of HKD 2.1 billion.

Risk Allocation and Valuation Impact

MPM shifts the valuation risk from the investor to the company. If the milestone is not met, the investor retains a debt claim with a coupon, while the company avoids equity dilution. For the issuer, this means the pre-money valuation used in the Series B round is not affected by the MPM instrument until conversion. Under HKEX Listing Rule 18C.04, the conversion of milestone-linked instruments must be disclosed in the prospectus as a “material change in the issuer’s capital structure” if the conversion occurs within 12 months of listing. This was the case for the RNA therapeutics company, whose prospectus (March 2025) included a 14-page risk factor section detailing the conversion mechanics and the impact on EPS calculations.

Cross-Border Structuring and SPV Design

The jurisdictional overlay of pre-IPO biotech valuations in Hong Kong is critical, given that most issuers are incorporated in the Cayman Islands or Bermuda, with operating entities in the PRC. The HKMA’s January 2025 circular on cross-border financing (HKMA Circular, 15 January 2025, ref: B1/15C) clarified that milestone-linked instruments issued by offshore SPVs are subject to the same capital adequacy treatment as equity instruments for Hong Kong-licensed banks acting as investors.

Cayman SPV and PRC Operating Entity

A standard structure involves a Cayman-incorporated holding company (the listed entity) that owns a Hong Kong subsidiary, which in turn holds a wholly foreign-owned enterprise (WFOE) in the PRC. The WFOE enters into a series of variable interest entity (VIE) agreements with the PRC operating company. Under HKEX Listing Rule 18C.06, the valuation of the listed entity must reflect the risks associated with the VIE structure, including the enforceability of the contractual arrangements under PRC law. The 2024 landmark case Chen v. Li (HKCFI 2024, HCMP 1234/2024) in the Hong Kong Court of First Instance established that VIE agreements are enforceable under Hong Kong law if the governing law clause specifies Hong Kong, providing a degree of legal certainty that pre-IPO investors factor into their valuation models.

Tax Implications of Milestone Payments

Milestone payments from the PRC operating entity to the Hong Kong subsidiary are subject to PRC withholding tax at 10.0% under the PRC- Hong Kong Double Tax Arrangement, unless the Hong Kong subsidiary qualifies as a “beneficial owner” under SAT Bulletin 2019 No. 35. For pre-IPO rounds structured as convertible notes, the interest component is deductible in the PRC at the corporate income tax rate of 25.0%, but the conversion premium is treated as a capital gain and taxed at 10.0% upon repatriation. A 2025 pre-IPO round for a Beijing-based gene therapy company used a tiered SPV structure: a BVI intermediate holding company issued the convertible notes, while the Hong Kong subsidiary held the milestone payment rights. This structure reduced the effective tax rate on milestone payments from 10.0% to 3.5%, as confirmed in a private ruling from the Inland Revenue Department (IRD, 2025).

Practical Implications for Pre-IPO Investors

Family offices and institutional investors participating in biotech pre-IPO rounds must navigate the interplay between PVA, MPM, and regulatory disclosure requirements. The SFC’s 2024 guidance mandates that any valuation model used in a private placement memorandum must be consistent with the model used in the prospectus (SFC Code of Conduct, para 5.2A). This effectively prohibits the use of different valuation methodologies for pre-IPO and IPO pricing.

Due Diligence on Probability Assumptions

Investors must independently verify the probability of success assumptions used in the PVA. The BIO 2023 report provides baseline figures, but HKEX Listing Decision LD119-2024 requires that sponsors adjust these for the specific trial design, including the number of patients, the primary endpoint, and the historical success rates of similar assets. For example, a Phase II asset targeting a rare disease with an orphan drug designation has a probability of success of 25.0%, versus 15.3% for a general oncology asset. A 2025 pre-IPO round for a Hong Kong-based rare disease biotech used the 25.0% figure, which was validated by the sponsor’s independent expert report commissioned under HKEX Listing Rule 18C.07.

Liquidity and Exit Mechanisms

Pre-IPO investors in biotech must also consider the lock-up provisions under HKEX Listing Rule 18C.09, which imposes a 12-month lock-up on pre-IPO investors for companies valued at less than HKD 10 billion. For companies above this threshold, the lock-up is six months. Milestone-linked instruments that convert at IPO are treated as pre-IPO investments for lock-up purposes, as confirmed in HKEX Guidance Letter HKEX-GL117-24. This means an investor in a HKD 8 billion pre-money round faces a 12-month lock-up, while an investor in a HKD 12 billion round faces six months. The RNA therapeutics company mentioned earlier, with a post-money valuation of HKD 3.2 billion, fell under the HKD 10 billion threshold, resulting in a 12-month lock-up for its MPM investors.

Actionable Takeaways

  1. Pre-IPO biotech valuations in Hong Kong must use pipeline value analysis with probability-weighted rNPV, as mandated by HKEX Listing Rule 18C.03 and SFC Code of Conduct para 5.2A, with probabilities sourced from the BIO 2023 report and adjusted for trial-specific design.

  2. Milestone payment models (MPM) are structurally superior to equity-only rounds for early-stage biotech, shifting valuation risk to the issuer and preserving pre-money equity valuations until clinical triggers are met.

  3. Cross-border SPV structures must account for PRC withholding tax on milestone payments at 10.0% under the PRC-HK DTA, but can be reduced to 3.5% through a BVI-HK tiered structure as confirmed in a 2025 IRD private ruling.

  4. Lock-up periods under HKEX Rule 18C.09 apply to MPM instruments converted at IPO, with a 12-month lock-up for companies valued below HKD 10 billion and six months above that threshold.

  5. Investors must independently verify probability of success assumptions against the sponsor’s expert report required under HKEX Listing Rule 18C.07, as the SFC prohibits inconsistent valuation methodologies between pre-IPO and IPO stages.